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Abstract 
Purpose: To develop a new spectrophotometric method for the analysis of losartan potassium in 
pharmaceutical formulations by making its complex with copper. 
Method: A coloured complex based on UV/Vis spectroscopic method was developed for the 
determination of losartan potassium concentration in pharmaceutical formulations in the visible region. 
The colored complex of losartan was formed with cupric acetate (5:4). Analysis was carried out by the 
two methods - absorption ratio and calibration curve methods. The proposed method was validated in 
terms of linearity, accuracy and precision.  
Results: The λ maximum of the complex was recorded at 530 nm.  Beer`s law was obeyed in the range 
of 10 - 50 µg/ml with a correlation coefficient (r2) of 0.9989. Mean analytical results from the calibration 
curve and absorption ratio methods were 99.42 and 99.16 % with relative standard deviation (RSD) of 
0.97 and 0.82 %, respectively. Mean recovery was between 98.61 and 101.35 % and precision 
expressed as relative standard deviation (RSD) was 0.91 %.  
Conclusion: The proposed method is simple, easy to apply, low-cost, and requires relatively 
inexpensive instruments. Thus, it is a suitable alternative to currently used spectrophotometric methods 
for the determination of losartan in bulk and solid dosage forms.   
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The potassium salt of losartan, 2-n-butyl-4-
chloro-5-hydroxymethyl- 1-((2-(1H-tetrazol-5-yl) 
(biphenyl-4-yl) methyl) imidazole, is a strong 
antihypertensive angiotensin II receptors blocker 
[1-3]. Copper is an essential transition element 
that plays a major role in the biochemistry of all 
aerobic organisms. This metal triggers a series of 
electron transfer reactions as a cofactor in a 
number of critical enzymatic pathways. These 
enzymes are essential for cellular respiration, 
iron homeostasis, pigment formation, 
neurotransmitter production, peptide biogenesis, 
connective tissue biosynthesis, and antioxidant 
defense [4,5].  
 
Molecular interactions between electron donors 
and electron acceptors are generally associated 
with the formation of intensely colored charge-
transfer complexes, which absorb radiation in the 
visible region [6]. The rapid formation of these 
complexes leads to their utility in the 
development of simple and convenient 
spectrophotometric methods for these 
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compounds [7-9]. The copper (II) complex of 
Losartan was obtained and characterized as a 
microcrystalline powder. Vibrational 
spectroscopy reveals that the metal center is 
bound to the ligand through the nitrogen atoms of 
the tetrazolate moiety. The antioxidant properties 
of the complex (superoxide dismutase mimetic 
activity) and its effect on the proliferation and 
morphology of two osteoblast-like cells in culture 
have been reported. The new compound exerted 
more toxic effects on tumoral cells than the 
copper (II) ion and losartan [10]. 
 
Analysis of losartan has been carried out in 
tablets and biological fluid by high performance 
liquid chromatography (HPLC) [11,12], capillary 
electrophoresis, super-critical fluid chromato-
graphy [13,14], and in urine by gas 
chromatography-mass spectrometry [15]. 
However, to the best of our knowledge, no UV-
Vis spectrophotometric method has been 
reported for the analysis of losartan-copper. The 
aim of the study, therefore, was to develop an 
easy, economical and sensitive 
spectrophotmetric method for the determination 
of losartan potassium in pharmaceutical 






Losartan potassium was received from Mass 
Pharma (Pvt) Ltd, Lahore, Pakistan as gift. 
Cupric acetate and glacial acetic acid (both 
manufactured by E. Merck Germany) were 




The method was constructed on the basis of 
drug complex analysis by UV/VIS 
spectrophotometer. For the preparation of drug 
complex, pure losartan potassium and cupric 
acetate were chosen. Different ratios of losartan 
potassium and cupric acetate for complex 
formation were prepared as indicated in Table 1. 
The complex was formed by first mixing varying 
amounts of accurately weighed losartan 
potassium with 50 ml of distilled water and 
filtered through Whatman filter paper (0.45 µm). 
Cupric acetate (varying amounts) was added to 
the filtrate with slight shaking for 5 min to achieve 
formation of the blue-colored complex of losartan 
potassium (Table 1). The colored complex was 
filtered through Whatman filter paper, ,dried at 
room temperature and accurately weighed. The 
drug/cupric acetate ratio that yielded the highest 
complex weight was chosen for method 
development. 








Weight of complex 
formed (mg) 
100 50 2.12 
100 60 2.57 
100 80 3.58 
100 100 3.56 
 
Selection of an appropriate solvent system 
 
Various solvent systems, including distilled 
water, Ethyl alcohol, Acetone, Cholorom and 
Glacial acetic acid, were tested to select an 
appropriate solvent with good solubility and 
stability of drug–copper complex. Glacial acetic 
acid was selected for developing spectral 
characteristics of drug due to the solubility of 
losartan-copper complex in this liquid.  
 
Determination of absorption maximum 
 
The color of copper is brownish showing 
absorption maximum (λmax) at 740 nm. Upon 
formation of complex, this color was immediately 
turned bluish and the absorption spectrum of 
losartan potassium-copper reaction product 
showed maximum absorption peak at 530 nm 
(Figure 1). This change in color indicated the 
formation of a charge-transfer complex between 
losartan potassium and copper. 
 
 
Figure 1:  Spectrum of losartan–copper complex 
showing absorption maximum at 530 nm 
 
Preparation of standard solution 
 
Pure losartan potassium powder (100 mg) was 
dissolved in 25 ml of water in a beaker and the 
solution filtered through Whatman filter paper; 80 
mg of cupric acetate was added to the filtrate and 
shaken for 5 min, producing a light blue complex. 
The complex was filtered through Whatman filter 
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paper, dried at room temperature and weighed. 
The whole complex formed was dissolved in a 
small amount of glacial acetic acid (10 ml), 
transferred to a 100 ml volumetric flask, made up 
to 100 ml with glacial acetic acid and shaken 
well. From this solution 10 ml was transferred to 
another 100 ml volumetric flask and made up to 
100 ml with glacial acetic acid. Finally, 10 ml of 
this solution was transferred to yet another 100 
ml volumetric flask and the volume again made 
up to 100 ml with glacial acetic acid. 
 
Preparation of sample solution 
 
Twenty tablets of losartan potassium of 50 mg 
strength each were weighed and ground them 
using a pestle and mortar. A portion of the 
powder containing 100 mg of losartan potassium 
was added to 25 ml of water, shaked well. 
Solution was then filtered. 80 mg of cupric 
acetate was added to the filtrate and shaken for 
5 min. A light blue color complex was formed 
which was then filtered, dried, dissolved in a 
small amount of glacial acetic acid (10 ml)  and 
transferred to a 100 ml volumetric flask. The 
volume of the solution was made up to the 100 
ml mark with glacial acetic acid. Out of this 
solution, 10 ml was transferred to another 100 ml 
volumetric flask and made up to 100 ml with 
glacial acetic acid. Finally, 10 ml of this was 
transferred to another 100 ml volumetric flask 
and made up to 100 ml with glacial acetic acid. 
  
Calibration curve method 
 
A calibration curve for losartan potassium copper 
complex, which obeyed Beer’s law was plotted. 
Absorbance was determined spectrophotop-
metrically using UV-2550, Shimadzu, Japan 
spectrophotometer at 530 nm and the drug 
content of the samples were computed 
 
Absorption ratio method 
 
The 530 nm wavelength was selected from the 
scanned spectrum of losartan copper complex, 
being the λ max of drug-copper complex .The 
ratio of the absorbance of the sample solution to 
that of the standard solution, expressed as a 
percentage, was taken as purity (%) 
  
Validation of the method  
 
The method was validated according to the ICH 






Linearity of the proposed methods was 
determined by analyzing the samples of losartan 




Accuracy of analysis was determined by 
systemic error method based on the closeness 
between the actual (true) value and analytical 
value and was obtained by applying the test in 
six replicates  
Accuracy may often be expressed as % 
recovery. This method is the measure of the 
exactness of the analytical method. Recovery 
experiment was carried out in triplicate by 
analyzing samples of the losartan copper 
complex (10 µg/ml) at three different 




System precision was estimated from 
repeatability and reproducibility. The Intraday 
and interday precision of the method were 
confirmed by measuring absorbance of six 
replicate samples of losartan copper complex 
three times in a day and also on two different 
days. Percentage relative standard deviation (% 




Data analysis was carried out using ANOVA 
using software, SPSS version 13.0. The level of 
significance was set at p < 0.05. 
    
RESULTS 
 
Mean drug content 
 
The assay results from calibration curve and 
absorption methods showed 99.42 and 99.16 % 
losartan content, respectively; the difference was 
non-significant (p > 0.05) and was not also 
different from the stated purity for the standard 
drug. These results indicate good accuracy of 
method (Table 2). 
 






Conc. 99.42 % 99.16 % 




The calibration curve had a small intercept (-
0.01) and was linear in the concentration range 
Hassan et al 
Trop J Pharm Res, June 2013;12 (3): 
 
410 





Percent recovery for losartan  was found to be in 
the range of 98.61 to 101.35 % (Table 3). 
 
Table 3: Recovery data for losartan potassium (mean 
± SD). 
 











10  1  10.08  101.35±1.22 









Precision was studied to find out intra- and inter-
day variation. Calibration curves prepared in the 
medium were run three times on the same day 
and continued for three days. %RSD (relative 
standard deviation) were calculated. Precision 
was < 2 %, and the data are given in Table 4. 
 
Table 4: Results of intermediate precision (mean ± 
%S.D) 
 





% Label claim  % Label claim  
Intra-day 101.40±0.75 99.89±0.66 
Inter-day 100.98±1.0 100.82±1.26 
   
DISCUSSION 
 
Various researchers have studied losartan 
potassium separately or in combination with 
other drugs in various dosage forms [14,16,17]. 
However, to the best of our knowledge, no 
analytical study regarding the determination of 
losartan potassium as a complex with copper 
ions using spectrophtometric technique has been 
reported. The complexes of drugs always 
showed better biological effects than drug alone. 
Based on previous studies, Saeed et al  [18] 
synthesized the drug-enzyme conjugate complex 
of dexamethasone – subtilisin enzyme and 
dexamethasone- cellulase in order to study their 
drug - protein ratio, immunoreactivity, enzyme 
activity, stability and proved that the drug - 
enzyme complex can be synthesized and 
characterized for better activity. Saeed et al [19] 
further investigated the enzyme activities for 
pepsin and its complexation with dexamethasone 
to study the immunoreactiv by rapid enzyme 
linked immunosorbent (ELISA) assay which 
proved that the complex was immunoreactive to 
dexamethasone specific antibodies. This study 
was useful for preparing a variety of drug - 
complex moieties.  
 
Losartan does not show antioxidant activity, its 
copper complex has displayed a moderately anti 
tumour activity. This effect cannot produced by 
the copper ion or the Losartan ligand itself even 
in higher concentration. So the resultant complex 
produces more toxic action on the tumour cells 
than the copper ion and losartan [10]. 
Ibrahim [20] reported an analytical study for the 
charge-transfer complexes of losartan 
potassium. The method was successfully applied 
to the analysis of tablets from different 
manufacturers that contain LOS-K, alone or 
combined with hydrochlorothiazide, with good 
accuracy and precision; recovery values were in 
the range of 98.96 ± 1.62 to 101.58 ± 1.29 %. 
‘ 
The aim of the present study was to carry out 
charge-transfer complexation reaction of losartan 
potassium (LOS-K) as electron donor and copper 
which is an electron acceptor. The accuracy of 
the method was confirmed by recovery results for 
tablet at three different levels of standard 
additions, in range of 95 – 110 % justifies the 
accuracy of this method. Olga et al [16] 
presented an analytical UV derivative 
spectrophotometric method to quantify losartan 
potassium used as a single active principle in 
pharmaceutical dosage forms. The mean 
recovery of the method was 100.7 ± 1.1 % and 
the precision (expressed as relative standard 
deviation) was 0.88 %.  
 
The present method is superior to previously 
reported UV-based spectrophotometric methods, 
because the measurements were performed in 
the visible region, away from the UV-absorbing 
region. Consequently, the colored complexes 
obtained can be utilized in the determination of of 





The charge-transfer complexation reaction of 
losartan potassium with copper has successfully 
been utilized in the development of a simple, 
rapid and accurate spectrophotometric method 
for the analysis of losartan potassium in 
pharmaceutical dosage forms. The developed 
methods, unlike previously reported methods, 
are not UV-based spectrophotometric methods, 
as the measurements were performed in the 
visible region. The developed method would be 
useful for routine quality control analysis of 
losartan potassium tablets. 
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